A nurse is teaching a 68-year-old client with atrial fibrillation about bridge anticoagulation in preparation for an elective laparoscopic cholecystectomy in 7 days. The client has been taking warfarin 5 mg daily with INR 2.4 and a CHA2DS2-VASc score of 4. Which teaching points are essential for safe peri-procedural management? Select all that apply.
Select All That Apply
Choose your responses, then check the answer.
Explanation
Bridge anticoagulation manages the risk of thromboembolism during temporary warfarin interruption for invasive procedures. For a CHA2DS2-VASc of 4 (moderate-to-high stroke risk), an evidence-based bridging plan: (1) stop warfarin 5 days pre-op so INR drifts below 1.5; (2) start therapeutic-dose LMWH (enoxaparin 1 mg/kg q12h) 36 hours after the last warfarin dose, last dose at least 24 hours before surgery to allow LMWH clearance; (4) resume warfarin on the evening of surgery and continue bridging LMWH until INR is therapeutic for 2 consecutive days. Continuing warfarin (option 6) creates major bleeding risk during laparoscopic surgery. IV vitamin K 10 mg (option 2) causes warfarin resistance for days. Switching chronic warfarin to aspirin (option 4) is inappropriate without electrophysiology consultation.
Bridge Anticoagulation Logic Stroke risk during warfarin hold is greater than the bleeding risk of LMWH bridging, so bridging is offered for moderate-to-high CHA2DS2-VASc.
Standard Schedule - Day -5: Stop warfarin - Day -3: Start therapeutic LMWH (36 hours after last warfarin) - Day -1: Last LMWH 24 hours pre-op - Day 0: INR less than 1.5 — surgery - Day 0 PM: Resume warfarin - Day +1 onward: LMWH continues until INR is therapeutic for 2 days
Wrong Answers 3: Continuing warfarin into surgery creates bleeding risk. 5: IV vitamin K induces warfarin resistance for days. 6: Switching to aspirin without specialist input is out of scope.
NCSBN Theme PPT — Adverse effects, bleeding and coagulation.
Scenario68-year-old, atrial fibrillation, on warfarin 5 mg daily, scheduled for elective lap chole in 7 days.
Plan- Bridge anticoagulation with LMWH- Stop warfarin 5 days pre-op- Therapeutic enoxaparin until 24 hours pre-op- Resume warfarin evening of surgery
Bridge anticoagulation — Strategy of replacing oral anticoagulant (warfarin) with a shorter-acting parenteral anticoagulant (LMWH or UFH) during a peri-procedural period to minimize both thromboembolism and bleeding risk. Indicated for moderate-to-high stroke risk (CHA2DS2-VASc 4 or higher in AF) or recent VTE within 3 months. Not needed for low-risk patients.
CHA2DS2-VASc — Stroke risk score in non-valvular atrial fibrillation: CHF (1), HTN (1), Age 75 or older (2), DM (1), Stroke or TIA (2), Vascular disease (1), Age 65 to 74 (1), Female sex (1). Score of 2 or more in men or 3 or more in women indicates chronic anticoagulation.
LMWH (enoxaparin) — Low-molecular-weight heparin — predictable pharmacokinetics, no PTT monitoring required. Therapeutic dose 1 mg/kg subcutaneous every 12 hours. Last dose 24 hours before surgery to allow clearance. Anti-Xa monitoring in renal failure or weight extremes. Reversal with protamine (incomplete).